Penn Medicine
Help | Search | Site Map | Contact   
> Perelman School of Medicine   > Faculty   > Details

Description of CVI Expertise

CVI Program Unit(s):
Myocyte Biology / Heart Failure
Pulmonary Vascular Disease

CVI Research Description:
My laboratory is investigating signaling mechanisms of pulmonary vascular smooth muscle cell proliferation and migration as it relates to pulmonary arterial hypertension (PAH). mTOR signaling modulates metabolic deregulationin in vascular smooth muscle in PAH; discovery of novel signaling network in VSM remodeling

Selected Publications

Obraztsova K, Basil MC, Rue R, Sivakumar A, Lin SM, Mukhitov AR, Gritsiuta AI, Evans JF, Kopp M, Katzen J, Robichaud A, Atochina-Vasserman EN, Li S, Carl J, Babu A, Morley MP, Cantu E, Beers MF, Frank DB, Morrisey EE, Krymskaya VP: mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline. Nature Communications 11(1): 5640, Nov 2020 Notes: https://doi.org/10.1038/s41467-020-18979-4.

Evans JF, Obraztsova K, Lin SM, Krymskaya VP : CrossTORC and Wntegration in disease: Focus on Lymphangioleiomyomatosis. International Journal of Molecular Sciences 22(5): 2233-2248, February 2021 Notes: doi.org/10.3390/ijms22052233.

Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, Kreider M: A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. Respiratory Medicine 163: 105898, Mar 2020 Notes: doi: 10.1016/j.rmed.2020.105898.

Evans JF, Rue RW, Mukhitov AR, Obraztsova K, Smith CJ, Krymskaya VP : Inhibition of growth of TSC2-null cells by a PI3K/mTOR inhibitor but not by a selective MNK1/2 inhibitor Biomolecules: Molecular Pathology, Molecular Mechanisms of Lung Diseases 10(1): 28, Dec 2019 Notes: doi: 10.3390/biom10010028.

Kovalenko A, Sanin A, Kosmas K, Zhang L, Wang J, Akl EW, Giannikou K, Probst CK, Hougard TR, Rue RW, Krymskaya VP, Asara JM, Lam HC, Kwiatkowski DJ, Henske EP, Filippakis H: Therapeutic targeting of DGKA-mediated macropinocytosis leads to phospholipid reprogramming in Tuberous Sclerosis Complex. Cancer Research 81(8): 2086-2100, Apr 2021 Notes: DOI: 10.1158/0008-5472.CAN-20-2218.

Li H, Oh HB, Viollet B, Schmidt LS, Linehan WM, Krymskaya VP, Hong SB: Requirement of FLCN tumor suppressor gene for mTORC1-mediated inhibition of TFE3 transcriptional activity. bioRxiv Jul 2020 Notes: doi: https://doi.org/10.1101/2020.07.08.193169.

Han F, Dellacecca ER, Barse LW, Cosgrove C, Henning SW, Ankney CM, Jaishankar D, Yemelyanov A, Krymskaya VP, Dilling DF, Le Poole IC: Adoptive T cell transfer to treat lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology 62(6): 793-804, Jun 2020 Notes: doi: 10.1165/rcmb.2019-0117OC.

Krymskaya VP, McCormack FX: Lymphangioleiomyomatosis: a monogenic model of malignancy. Annual Review of Medicine 68: 69-83, Jan 2017 Notes: NIHMSID: 889033.

back to top
Last updated: 10/25/2021
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with a supported browser.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration